Back to results
US 2019/0338030 A1Published application
Novel anti-b7h3 binding compounds and uses thereof
AssigneeFull Spectrum Genetics, Inc.
InventorsRobert DuBridge, Veronica Juan
Life of this patent
Estimating the term…
Abstract
The invention is directed to novel antibody binding compounds specific for the human B7H3 and uses of such compounds for diagnostic and therapeutic purposes.
Claims22
1-2. (canceled)
An antibody binding compound specific for the human B7H3 comprising a heavy chain of the following form:
- f1-HC1-f2-HC2-f3-HC3-f4
- and light chain of the following form:
- g1-LC1-g2-LC2-g3-LC3-g4
- wherein f1, f2, f3 and f4 are human heavy chain framework residues;
- g1, g2, g3 and g4 are human light chain framework residues;
- and HC1, HC2, HC3, LC1, LC2 and LC3 are complementary determining regions (CDRs) defined by the following amino acid sequences:
- HC1:
- (SEQ ID NO:
- 1)
- N-Y-D-I-N;
- HC2:
- (SEQ ID NO:
- 9)
- W-I-F-P-G-D-G-S-T-Q-Y-N-G-K-F-K-G;
- HC3:
- (SEQ ID NO:
- 10)
- Q-T-T-G-T-W-F-A-Y;
- LC1:
- (SEQ ID NO:
- 11)
- R-A-S-Q-S-I-S-P-Y-L-H;
- LC2:
- (SEQ ID NO:
- 12)
- Y-A-S-Q-S-W-S;
- and
- LC3:
- (SEQ ID NO:
- 6)
- Q-N-G-H-S-F-P-L-T,
28 more elements
An antibody binding compound specific for the human B7H3 comprising a heavy chain of the following form:
- f1-HC1-f2-HC2-f3-HC3-f4
- and light chain of the following form:
- g1-LC1-g2-LC2-g3-LC3-g4
- wherein f1, f2, f3 and f4 are human heavy chain framework residues;
- g1, g2, g3 and g4 are human light chain framework residues;
- and HC1, HC2, HC3, LC1, LC2 and LC3 are complementary determining regions (CDRs) defined by the following amino acid sequences:
- HC1:
- (SEQ ID NO:
- 1)
- N-Y-D-I-N;
- HC2:
- (SEQ ID NO:
- 15)
- W-I-F-P-G-D-G-S-T-Q-Y-N-E-T-F-K-G;
- HC3:
- (SEQ ID NO:
- 10)
- Q-T-T-G-T-W-F-A-Y;
- LC1:
- (SEQ ID NO:
- 16)
- R-A-S-Q-S-I-S-K-Y-L-H;
- LC2:
- (SEQ ID NO:
- 17)
- Y-A-N-Q-S-I-R;
- and
- LC3:
- (SEQ ID NO:
- 6)
- Q-N-G-H-S-F-P-L-T.
28 more elements
An antibody binding compound specific for the human B7H3 comprising a heavy chain of the following form:
- f1-HC1-f2-HC2-f3-HC3-f4
- and light chain of the following form:
- g1-LC1-g2-LC2-g3-LC3-g4
- wherein f1, f2, f3 and f4 are human heavy chain framework residues;
- g1, g2, g3 and g4 are human light chain framework residues;
- and HC1, HC2, HC3, LC1, LC2 and LC3 are complementary determining regions (CDRs) defined by the following amino acid sequences:
- HC1:
- (SEQ ID NO:
- 1)
- N-Y-D-I-N;
- HC2:
- (SEQ ID NO:
- 20)
- W-I-F-P-G-D-G-S-T-Q-Y-N-P-K-F-K-G;
- HC3:
- (SEQ ID NO:
- 10)
- Q-T-T-G-T-W-F-A-Y;
- LC1:
- (SEQ ID NO:
- 21)
- R-A-S-Q-S-I-S-T-Y-L-H;
- LC2:
- (SEQ ID NO:
- 22)
- E-A-S-Q-S-I-S;
- and
- LC3:
- (SEQ ID NO:
- 6)
- Q-N-G-H-S-F-P-L-T.
28 more elements
An antibody binding compound specific for the human B7H3 comprising a heavy chain of the following form:
- f1-HC1-f2-HC2-f3-HC3-f4
- and light chain of the following form:
- g1-LC1-g2-LC2-g3-LC3-g4
- wherein f1, f2, f3 and f4 are human heavy chain framework residues;
- g1, g2, g3 and g4 are human light chain framework residues;
- and HC1, HC2, HC3, LC1, LC2 and LC3 are complementary determining regions (CDRs) defined by the following amino acid sequences:
- HC1:
- (SEQ ID NO:
- 1)
- N-Y-D-I-N;
- HC2:
- (SEQ ID NO:
- 25)
- W-I-F-P-G-D-G-S-T-Q-Y-N-E-K-F-K-G;
- HC3:
- (SEQ ID NO:
- 10)
- Q-T-T-G-T-W-F-A-Y;
- LC1:
- (SEQ ID NO:
- 26)
- R-A-S-Q-S-I-S-H-Y-L-H;
- LC2:
- (SEQ ID NO:
- 27)
- Y-A-S-Q-S-L-S;
- and
- LC3:
- (SEQ ID NO:
- 6)
- Q-N-G-H-S-F-P-L-T.
28 more elements
An antibody binding compound specific for the human B7H3 comprising a heavy chain of the following form:
- f1-HC1-f2-HC2-f3-HC3-f4
- and light chain of the following form:
- g1-LC1-g2-LC2-g3-LC3-g4
- wherein f1, f2, f3 and f4 are human heavy chain framework residues;
- g1, g2, g3 and g4 are human light chain framework residues;
- and HC1, HC2, HC3, LC1, LC2 and LC3 are complementary determining regions (CDRs) defined by the following amino acid sequences:
- HC1:
- (SEQ ID NO:
- 1)
- N-Y-D-I-N;
- HC2:
- (SEQ ID NO:
- 25)
- W-I-F-P-G-D-G-S-T-Q-Y-N-E-K-F-K-G;
- HC3:
- (SEQ ID NO:
- 10)
- Q-T-T-G-T-W-F-A-Y;
- LC1:
- (SEQ ID NO:
- 11)
- R-A-S-Q-S-I-S-P-Y-L-H;
- LC2:
- (SEQ ID NO:
- 30)
- H-A-S-Q-S-I-S;
- and
- LC3:
- (SEQ ID NO:
- 6)
- Q-N-G-H-S-F-P-L-T.
28 more elements
An antibody binding compound specific for the human B7H3 comprising a heavy chain of the following form:
- f1-HC1-f2-HC2-f3-HC3-f4
- and light chain of the following form:
- g1-LC1-g2-LC2-g3-LC3-g4
- wherein f1, f2, f3 and f4 are human heavy chain framework residues;
- g1, g2, g3 and g4 are human light chain framework residues;
- and HC1, HC2, HC3, LC1, LC2 and LC3 are complementary determining regions (CDRs) defined by the following amino acid sequences:
- HC1:
- (SEQ ID NO:
- 1)
- N-Y-D-I-N;
- HC2:
- (SEQ ID NO:
- 25)
- W-I-F-P-G-D-G-S-T-Q-Y-N-E-K-F-K-G;
- HC3:
- (SEQ ID NO:
- 33)
- Q-T-T-S-T-W-F-A-Y;
- LC1:
- (SEQ ID NO:
- 34)
- R-A-S-Q-I-I-S-D-Y-L-H;
- LC2:
- (SEQ ID NO:
- 35)
- Y-A-S-Q-L-I-S;
- and
- LC3:
- (SEQ ID NO:
- 6)
- Q-N-G-H-S-F-P-L-T.
28 more elements
An antibody binding compound specific for the human B7H3 comprising a heavy chain of the following form:
- f1-HC1-f2-HC2-f3-HC3-f4
- and light chain of the following form:
- g1-LC1-g2-LC2-g3-LC3-g4
- wherein f1, f2, f3 and f4 are human heavy chain framework residues;
- g1, g2, g3 and g4 are human light chain framework residues;
- and HC1, HC2, HC3, LC1, LC2 and LC3 are complementary determining regions (CDRs) defined by the following amino acid sequences:
- HC1:
- (SEQ ID NO:
- 1)
- N-Y-D-I-N;
- HC2:
- (SEQ ID NO:
- 25)
- W-I-F-P-G-D-G-S-T-Q-Y-N-E-K-F-K-G;
- HC3:
- (SEQ ID NO:
- 10)
- Q-T-T-G-T-W-F-A-Y;
- LC1:
- (SEQ ID NO:
- 38)
- R-A-S-Q-S-I-S-E-Y-L-H;
- LC2:
- (SEQ ID NO:
- 30)
- H-A-S-Q-S-I-S;
- and
- LC3:
- (SEQ ID NO:
- 6)
- Q-N-G-H-S-F-P-L-T.
28 more elements
Dependencies are inferred from the claim text.